Trial watch: anticancer vaccination with dendritic cells.
(2024) OncoImmunology — Vol. 13, n° 1, p. 2412876 [1-16] (2024)
Files
Trial_watch.pdf
Open Access - Adobe PDF
- 1.24 MB
Details
- Authors
Vigneron, Nathalie 
Garg, Abhishek D
- Abstract
- Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing them with tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), and utilizing maturation cocktails to ensure their effective activation. These matured DCs are then reinfused to elicit tumor-specific T-cell responses. While this approach has demonstrated the ability to generate potent immune responses, its clinical efficacy has been limited due to the immunosuppressive tumor microenvironment. Recent efforts have focused on enhancing the immunogenicity of DC-based vaccines, particularly through combination therapies with T cell-targeting immunotherapies. This Trial Watch summarizes recent advances in DC-based cancer treatments, including the development of new preclinical and clinical strategies, and discusses the future potential of DC-based vaccines in the evolving landscape of immuno-oncology.
- Affiliations
Citations
Borges, F., Laureano, R. S., Vanmeerbeek, I., Sprooten, J., Demeulenaere, O., Govaerts, J., Kinget, L., Saraswat, S., Beuselinck, B., De Vleeschouwer, S., Clement, P., De Smet, F., Sorg, R. V., Datsi, A., Vigneron, N., Naulaerts, S., & Garg, A. D. (2024). Trial watch: anticancer vaccination with dendritic cells. OncoImmunology, 13(1), 2412876 [1-16]. https://doi.org/10.1080/2162402X.2024.2412876 (Original work published 2024)